GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open-House-Rabattverträge 2025-07

Health, Health, Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

July 30, 2027
Response Due
Active
Status

About this record

The issuing agency did not publish a description for this notice. The full record as GlobalGov received it is below.

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start a free GlobalGov account

Solicitation Details

Issuing agencyHealth, Health, Health
CountryGermany
CategoryPharmaceuticals
PublishedJune 20, 2025
Procurement stageActive solicitation
Response dueJuly 30, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Epoetin zeta
Germany – Pharmaceutical products – Arnzeimittelverträge mit Beitrittsoption
Germany – Pharmaceutical products – Open house drug discount contracts for the active ingredient Bimekizumab, ATC L04AC21
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Timolol und Brinzolamid, ATC S01ED67
Germany – Pharmaceutical products – Conclusion of a non-exclusive drug discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) by way of an open-house model for the active ingredient tocilizumab (WHO ATC code: L04AC07)
Germany – Pharmaceutical products – Open house drug discount contracts Iron(III) derisomaltose, ATC B03AC08
Germany – Pharmaceutical products – Conclusion of non-exclusive agreements for medicinal products containing the active ingredient fremanezumab (ATC code: N02CD03) via an open-house model
Germany – Pharmaceutical products – Open framework agreement on drug discounts pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V), with the possibility of joining at any time, so-called approval model 2025-09

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.